Edwards Lifesciences (EW)
79.78
+0.86 (1.09%)
NYSE · Last Trade: Feb 20th, 4:58 PM EST

Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.
Via The Motley Fool · February 20, 2026
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for an enterprise value of approximately $14.5 billion. This transaction, structured as a mix of 73% cash
Via MarketMinute · February 19, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · February 17, 2026
Edwards Lifesciences Corp (NYSE:EW) Reports Mixed Q4 Results, Misses EPS Estimateschartmill.com
Via Chartmill · February 10, 2026
The U.S. mergers and acquisitions (M&A) landscape has entered a definitive new era in early 2026, marked by what analysts are calling a "Strategic Rebound." After years of aggressive antitrust intervention and a "litigation-first" posture from federal regulators, the tide has turned toward regulatory pragmatism. Large-cap companies, once
Via MarketMinute · February 13, 2026
Via MarketBeat · February 12, 2026
Unusual volume S&P500 stocks in Wednesday's sessionchartmill.com
Via Chartmill · February 11, 2026

Edwards Lifesciences (EW) Earnings Transcript
Via The Motley Fool · February 10, 2026
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal represents the largest acquisition for Boston Scientific in over two decades, signaling a transformative
Via MarketMinute · February 5, 2026
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.5 billion. The deal represents one of the most significant consolidations in the history of the medical
Via MarketMinute · January 27, 2026
Via MarketBeat · January 25, 2026
The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence (AI)-integrated imaging software. This strategic realignment resulted in a massive $25.7 billion year-over-year jump in deal value for the diagnostics and
Via MarketMinute · January 23, 2026
As we enter the early weeks of 2026, the American corporate landscape is still adjusting to a fundamental shift in the mechanics of growth. It has been nearly one year since the most significant overhaul of the Hart-Scott-Rodino (HSR) Act in five decades took effect on February 10, 2025. What
Via MarketMinute · January 23, 2026
MARLBOROUGH, MA – In a move that has sent shockwaves through the medical device sector, Boston Scientific Corporation (NYSE:BSX) announced today, January 15, 2026, a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for approximately $14.5 billion. The blockbuster deal, the largest in the industry since the early 2020s,
Via MarketMinute · January 15, 2026
As the financial markets open for the 2026 calendar year, BTIG has released its highly anticipated "Top Picks" report for the first half of the year, signaling a transition from the speculative fervor of 2025 toward a more fundamental, "constructive but selective" investment landscape. The firm’s analysts have identified
Via MarketMinute · January 2, 2026
As the final trading bells of 2025 ring out across Wall Street, the US Dollar is staging a defiant last-minute stand. After a year defined by dizzying volatility—ranging from a massive early-year surge to a historic mid-summer slump—the greenback is closing December on a high note. This eleventh-hour
Via MarketMinute · December 31, 2025
Edwards Lifesciences (EW) shows strong technicals and a high-quality consolidation pattern, suggesting a potential breakout trade setup for chart-focused investors.
Via Chartmill · December 26, 2025
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · December 16, 2025
Edwards Lifesciences (EW) Earnings Transcript
Via The Motley Fool · November 27, 2025
Edwards Lifesciences (EW) stock shows strong technical momentum and a high-quality breakout setup, poised for a potential move above key resistance.
Via Chartmill · November 27, 2025
Andreas Halvorsen of Viking Global Investors' portfolio Q3 changes included exits from Amazon, Nvidia and Qualcomm.
Via Benzinga · November 17, 2025
Via Benzinga · November 11, 2025
Via Benzinga · November 4, 2025
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive.
Via Benzinga · October 31, 2025
Edwards Lifesciences beats Q3 earnings, raises full-year guidance on strong structural heart portfolio growth and robust TAVR & TMTT sales.
Via Chartmill · October 30, 2025